

Modulation of Immune Effector and Regulator Cells by Sunitinib: Potential for Combination Therapy in Renal Cell Carcinoma Patients

**James Finke PhD,¹ Brian Rini MD,¹ Jennifer Ko MD PhD¹, Pat Rayman,¹
Dan Lindner MD PhD¹, Ernie Borden MD¹ Patricia A. Parsons-Wingerter, PhD²
Walter Storkus⁴ PhD and Peter Cohen³ MD**

Cleveland Clinic¹, John Glenn NASA Research Center², Mayo Clinic Arizona³ and UPMC⁴



Outline

- 1) Modulation of Immune Cells by sunitinib in RCC patients
- 2) Sunitinib combined with vaccine in B16.OVA Tumor Model
- 3) Suppressive and angiogenic activity of G-MDSC and neutrophils
- 4) MDSC role in sunitinib resistance




Renal Cell Carcinoma (RCC)

- ~50,000 new cases in US/year with ~13,000 deaths
- Incidence rising >2.5%/year
- Renal cell carcinoma arising from the renal cortex is responsible for 80-85% of all kidney cancers.
- It is an aggressive tumor that often has spread beyond the kidney before being diagnosed.
- Most common histological form of RCC is clear cell (>85%)
- Common to have mutation/inactivation of the VHL tumor suppressor gene.
- Unresponsive to modern chemotherapy or radiotherapy
- Anti-angiogenic receptor tyrosine-kinase inhibitors (RTKIs) now first-line therapy
 - **sunitinib (Sutent)**
 - **sorafenib (Nexavar)**



Multitargeted Approaches in mRCC: Sunitinib (Sutent)


- Small-molecule receptor tyrosine kinase inhibitor¹
- Inhibits all VEGFRs, PDGFR-A, PDGFR-B, c-KIT, and FLT-3¹
- Oral administration¹
- Both antitumor and antiangiogenic activity¹
- FDA approved January 26, 2006 for treatment of advanced RCC²
- 45% response rate in mRCC




- Treatment schedule-50mg daily for 4 weeks + 2 weeks off = one cycle

MDSC Isolated from RCC Patient's Tumor

A.






B.



b= band cell
 p= polymorphoneuclear
 m=monocyte
 i=immature




MDSC subsets RCC patients




Changes in MDSC and MDSC Subpopulations Following 1, 2, and 4 Cycles of Sunitinib


A. MDSC (Total Population) (n=24)




B. G-MDSC (n=25)




C. M-MDSC (n=15)




D. lin(-) MDSC (n=15)





Modulation of Myeloid DC by Sunitinib




Myeloid DCs (CD1c)(BDCA1+CD19- (—)),
Plasmacytoid DCs (pDC)(BDCA2+CD14-BDCA1- (—))




Reduction in G-MDSC Coincides with Increased T cell IFN γ Production




Absolute change in MDSC after 2 cycles of treatment



MDSC and T cells ability to produce IFN γ in RCC Tissue Post Sunitinib Treatment



Pazopanib Treated Patients



n=12 pts



Conclusions:

- 1. Sunitinib mediates reversal of MDSC accumulation in peripheral blood of RCC patients and enhances T cell IFN γ production.**
- 2. Sunitinib at concentrations achievable in plasma do not inhibit T cell proliferation or production of cytokine/chemokines *in vitro*.**
- 3. Sunitinib decreases the number of myeloid DC in the peripheral blood.**
- 4. Sunitinib-mediated MDSC decline in RCC patients was not correlated with changes in tumor volume. However, preliminary findings suggest that reduced levels of MDSCs after two cycle of therapy was associated with progression-free survival (p=.005).**
- 5. Preliminary analysis of tumors from sunitinib treated patients in a neoadjuvant setting show variability in MDSC reduction and T cell function.**
- 6. Pazopanib is also effective at reducing MDSC levels and promoting T cell IFN γ production.**




Combining Sunitinib with Immunotherapy




Superior Anti-Tumor Efficacy of Vaccine + TKI Co-Therapy

MO5 (B16.OVA)
injected s.c.
(2×10^5)




+/- oral Sunitinib
(0.1 mg/day, d10-16)
+/- s.c. DC1/OVA₂₅₇₋₂₆₂
vaccines d10, d17


Monitor tumor size
TME analysis (d34)
Immune monitoring (d34)




Vaccine/TKI Co-Therapy Promotes the Inhibition of Suppressor Cells and the Activation/Recruitment of Protective CD8⁺ T cells





Combination Treatment with Vaccine and Sunitinib Improved T cell Response



Combination Therapy Results in a Type-1 Biased Immune Profile in the Tumor



The Anti-tumor Efficacy of Combined Sunitinib/Vaccine Therapy is CXCR3 and VCAM-1 Dependent



Conclusions

- **Sunitinib improves anti-tumor efficacy when combined with specific immunization as a combinational therapy.**
- **Combinational therapy associated with reductions in MDSC and Treg frequencies in the TME**
- **Therapeutic benefits correlated with vaccine-induced CD8+ TIL frequencies (tetramer)**



Sunitinib Combined with Immunotherapy in Murine Tumor Models

- Ozao-Choy et. al. J Cancer Res 69:2514, 2009
4-1BBLigand/IL12(adenoviral vector)/sunitinib (MCA26)
- Bose A et. al. Int J Cancer 129: 2158, 2010
OVA-DC vaccine /sunitinib (B16-OVA)
- Farsaci et. al. Int J Cancer 130:1948, 2012
Poxvirus-based vaccine (CEA) /sunitinib
- Kujawski et. al. Cancer Res 70:9599, 2010
CD8⁺T cells/sunitinib(Renca)



Therapeutic Tumor Blood Vessel Antigen (TBVA) Targets

	<u>Cells Expressing</u>	<u>Aliases</u>	<u>Comments</u>
DLK-1	Pericytes "Stemmy" cells	Delta-like 1 homologue Preadipocyte factor 1 Fetal Antigen 1	NOTCH ligand (antagonist) EGF Family Member Shed by ADAM17/TACE Inhibits adipogenesis.
EphA2	VEC	ECK	RTK; binds ephrin A1, A5 Involved in angiogenesis, migration; poor prognosis
HBB	Pericytes	Hemoglobin- β (CD113t-C)	Expressed by pericyte progenitors (from hemangioblasts)
NRP1	Pericytes >> VEC	Neuropilin-1 (CD304)	Co-receptor for VEGF/ semaphorin 3A; Involved in angiogenesis, axon guidance, and cell survival & migration
RGS5	Pericytes	Reg. G-protein signaling 5	Regulates heterotrimeric G proteins as a GTPase activator; Hypoxia-responsive.
TEM1	Pericytes, VEC	Endosialin (CD248)	Binds fibronectin/collagen, Role in cell migration

Zhao X et al J Immunol 188:1782, 2012

Zhao X et al Molecular Therapy 19:805,2011




Overexpression of TBVA Transcripts in Tumor Versus Normal Adjacent Kidney (NAK): Real-Time RT-PCR (Mean +/- SD)

**Ratio of RCC/NAK
mRNA expression (N = 6)**

Antigen	Pericyte	VEC
CD31	-	0.8 ± 0.5
DLK1	52.4 ± 3.1	5.4 ± 1.6
EphA2	-	6.5 ± 2.6
HBB	37.5 ± 4.3	7.6 ± 3.2
NG2	1.3 ± 0.8	-
NRP1	8.8 ± 3.4	0.6 ± 0.5
PDGFRβ	13.7 ± 4.2	-
RGS5	9.5 ± 3.2	1.0 ± 0.6
TEM1	14.6 ± 6.1	0.4 ± 0.6
VEGFR1	3.5 ± 1.1	2.1 ± 0.6
VEGFR2	2.7 ± 0.7	1.7 ± 1.2
αSMA	2.2 ± 1.0	0.2 ± 0.4



Sunitinib-Induced Alterations in Type-1 T Cell Response to Vascular Antigens in HLA-A2⁺ RCC Patients (d35 versus d0; IFN- γ real-time)



T cell Response Against Antigen	Patient 1	Patient 2
HIV-nef [-]	-	-
FluM1 [+]	0.95	1.03
DLK1	4.86	0.97
EphA2	6.49	1.16
HBB	1.87	0.93
NG2	0.96	1.02
NRP1	1.10	0.91
RGS5	1.57	1.13
TEM1	2.12	3.74
VEGFR1	0.91	1.07
VEGFR2	1.16	0.96
G250	2.94	4.18



A Randomized Phase II Pilot Trial of Type-1-Polarized Autologous Dendritic Cell Vaccines Incorporating TBVA Peptides In Combination With SUNITINIB (SUTENT®) In Patients with Metastatic Clear Cell Carcinoma of the Kidney

HLA-A2⁺ Therapy-Naïve Patients
With Metastatic Clear Cell
Carcinoma of the Kidney

RANDOMIZE

ARM A
14 Pts

Cycle 1:
Vaccine Only
Wk 1, 3, 5

Cycle 2:
Vaccine (Wk 7, 10)
+ Sunitinib

ARM B
14 Pts

Cycle 1:
Vaccine (Wk 1, 3, 5)
+ Sunitinib

Cycle 2:
Vaccine (Wk 7, 10)
+ Sunitinib

FOLLOW-UP/RE-TREAT

VAC = α DC1 (10^7) + TBVA Peptide Pool (DLK1, EphA2, HBB, NRP1, RGS5, TEM1), s.c.

SUT = 50 mg/day

Primary Endpoint

- Specific Immune response rate in PBMC (MHC/peptide dextramers)

Secondary Endpoints


- Clinical response rate
- CD8⁺ TIL in tumor biopsy pre/post
- Suppressor cell reduction tumor/blood
- Reduction in tumor blood vessel density
- Increased CXCR3 ligand chemokine levels in serum



Suppressive and Angiogenic Activity of G-MDSC in RCC Patients




RCC Patient CD15+ MDSC Suppress T cells




(Representative of 8 Exp)

Suppression of T cells by G-MDSC & Neutrophils from RCC Patient & Normal





G-MDSC From RCC Patients Relative to Neutrophils Have a Significant Population of CD16⁺low population.

Gated on CD66b⁺CD33⁺low









Angiogenic Proteome Profile Array







G-MDSC and Patient Neutrophils are Proangiogenic in vivo- Xenograft Nude Mouse Model





Nude Mouse Xenograft Model of Angiogenesis



MDSC in 4T1 Tumor Bed Are Relative Resistant to Sunitinib Compared to MDSC in Renca



MDSC Persistence in RCC Tissue Post Sunitinib Treatment (Neoadjuvant)



Conclusions:

- G-MDSC and neutrophils isolated from RCC patients are immunosuppressive.
- Tumor conditioned medium from RCC cell lines can activate neutrophils from healthy donors to acquire suppressive activity.
- This activation causes degranulation of neutrophils with release of T cell suppressive arginase and angiogenic MMP9.
- Granulocytic MDSC and activated neutrophils may promote increase in tumor vasculature.
- Persistence of MDSC after sunitinib treatment in the tumor may promote resistant in some patients and mouse tumor models.
- Tumor derived products including GM-CSF may protect MDSC from sunitinib mediated apoptosis.





Lab members

Patricia Rayman, Yu Yang MD, Joanna Ireland,

Dr. Kausik Biswas (PhD), Soumika Biswas

Dr. Charles Tannenbaum PhD

Collaborators

Brian Rini MD

Peter Cohen MD, Mayo Clinic AR

Walter Strokus PhD, UPMC

Ernest Borden MD

Daniel Lindner MD PhD

Kevin Bunting PhD

Mike Vogelbaum MD

Baisakhi Raychaudhuri PhD

**Patricia A. Parsons-Wingerter
PhD**

Jennifer Ko MD PhD

**Grant Support - NIH, Pfizer Corporation, and
GlaxoSmithKline**

